Texas Capital Foundation Awards $250,000 to Texas Nonprofits Annual Honors Award program celebrates four organizations that are building a stronger Texas DALLAS, May 14, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the recipients of its 2025 Honors Awards. Launched in 2022, the Honors Awards are a signature initiative of the Texas Capital Foundation, awarding $250,000 in total annually to four organizations dedicated to addressing community needs across the state. “We are proud to honor four nonprofits as...
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236), a RAS(ON) mul...
Texas Capital Announces Expansion of Corporate and Investment Banking Division Significant platform investments support advisory, capital markets and trading capabilities DALLAS, May 07, 2025 (GLOBE NEWSWIRE) -- Texas Capital Securities, a subsidiary of Texas Capital Bancshares, Inc. (NASDAQ: TCBI), today announced a significant expansion of the services offered by its Corporate and Investment Bank. The additions to personnel and corresponding enhancements in capabilities build upon the firm’s existing industry-focused Corporate Banking expertise, with significant impact on the breadth ...
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.